Lineage Cell Therapeutics Total Revenue

Lineage Cell Therapeutics (LCTX) currently reports a total revenue of $13M as of June 2026. That compares with $11M in the prior-year period — up 19.9% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Lineage Cell Therapeutics's total revenue history and peer comparisons.

Lineage Cell Therapeutics's total revenue increased from $11M to $13M — a 19.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Lineage Cell Therapeutics's total revenue of $13M is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Lineage Cell Therapeutics reported $13M in total revenue as of June 2026. That compares with $11M in the prior-year period — up 19.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $13M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Lineage Cell Therapeutics, and consider following LCTX for alerts when major investors trade the stock.